Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline RiskKABBINAVAR, Fairooz; IRL, Cornelia; ZURLO, Alfredo et al.Oncology. 2008, Vol 75, Num 3-4, pp 215-223, issn 0030-2414, 9 p.Article

Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancerHURWITZ, Herbert; KABBINAVAR, Fairooz.Oncology. 2005, Vol 69, pp 17-24, issn 0030-2414, 8 p., SUP3Article

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer : Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical TrialsKABBINAVAR, Fairooz F; HURWITZ, Herbert I; JING YI et al.Journal of clinical oncology. 2009, Vol 27, Num 2, pp 199-205, issn 0732-183X, 7 p.Article

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort StudyKOZLOFF, Mark F; BERLIN, Jordan; FLYNN, Patrick J et al.Oncology. 2010, Vol 78, Num 5-6, pp 329-339, issn 0030-2414, 11 p.Article

Combined analysis of efficacy : The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerKABBINAVAR, Fairooz F; HAMBLETON, Julie; MASS, Robert D et al.Journal of clinical oncology. 2005, Vol 23, Num 16, pp 3706-3712, issn 0732-183X, 7 p.Article

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimenCLOUGHESY, Timothy F; FILKA, Emese; NELSON, Gillian et al.American journal of clinical oncology. 2002, Vol 25, Num 2, pp 204-208, issn 0277-3732Article

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesCASSIDY, James; SALTZ, Leonard B; GIANTONIO, Bruce J et al.Journal of cancer research and clinical oncology. 2010, Vol 136, Num 5, pp 737-743, issn 0171-5216, 7 p.Article

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancerSMALL, Eric J; FONTANA, Joseph; TANNIR, Nizar et al.BJU international (Papier). 2007, Vol 100, Num 4, pp 765-769, issn 1464-4096, 5 p.Article

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort studyKABBINAVAR, Fairooz F; FLYNN, Patrick J; KOZLOFF, Mark et al.European journal of cancer (1990). 2012, Vol 48, Num 8, pp 1126-1132, issn 0959-8049, 7 p.Article

Functional and Oncological Outcomes of Partial Nephrectomy of Solitary Kidneys. CommentaryLA ROCHELLE, Jeffrey; SHUCH, Brian; RIGGS, Stephen et al.The Journal of urology. 2009, Vol 181, Num 5, pp 2037-2043, issn 0022-5347, 7 p.Article

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerKABBINAVAR, Fairooz; HURWITZ, Herbert I; FEHRENBACHER, Louis et al.Journal of clinical oncology. 2003, Vol 21, Num 1, pp 60-65, issn 0732-183X, 6 p.Article

Fuhrman Grade Provides Higher Prognostic Accuracy Than Nucleolar Grade for Papillary Renal Cell CarcinomaKLATTE, Tobias; ANTERASIAN, Christine; SAID, Jonathan W et al.The Journal of urology. 2010, Vol 183, Num 6, pp 2143-2147, issn 0022-5347, 5 p.Article

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodBRITTEN, Carolyn D; KABBINAVAR, Fairooz; HECHT, J. Randolph et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 515-524, issn 0344-5704, 10 p.Article

Multicenter phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinomaVAUGHN, David J; BROWN, Archie W; HARKER, W. Graydon et al.Cancer. 2004, Vol 100, Num 4, pp 746-750, issn 0008-543X, 5 p.Article

Performance Status and Cytoreductive Nephrectomy : Redefining Management in Patients With Poor PerformanceSHUCH, Brian; LA ROCHELLE, Jeff C; WU, Jon et al.Cancer. 2008, Vol 113, Num 6, pp 1324-1331, issn 0008-543X, 8 p.Article

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerHURWITZ, Herbert; FEHRENBACHER, Louis; FERRARA, Napoleone et al.The New England journal of medicine. 2004, Vol 350, Num 23, pp 2335-2342, issn 0028-4793, 8 p.Article

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non―Small-Cell Lung CancerJOHNSON, Bruce E; KABBINAVAR, Fairooz; RUBIN, Mark et al.Journal of clinical oncology. 2013, Vol 31, Num 31, pp 3926-3934, issn 0732-183X, 9 p.Article

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabSCAPPATICCI, Frank A; SKILLINGS, Jamey R; HURWITZ, Herbert et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 16, pp 1232-1239, issn 0027-8874, 8 p.Article

A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non―Small-Cell Lung CancerHIRSCH, Fred R; KABBINAVAR, Fairooz; RUSK, Jason et al.Journal of clinical oncology. 2011, Vol 29, Num 26, pp 3567-3573, issn 0732-183X, 7 p.Article

Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancerJUBB, Adrian M; HURWITZ, Herbert I; HILLAN, Kenneth et al.Journal of clinical oncology. 2006, Vol 24, Num 2, pp 217-227, issn 0732-183X, 11 p.Article

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimenCLOUGHESY, Timothy F; FILKA, Emese; KUHN, John et al.Cancer. 2003, Vol 97, Num 9, pp 2381-2386, issn 0008-543X, 6 p., SUPConference Paper

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinomaSCHÖFFSKI, Patrick; GARCIA, Jorge A; MIN ZHU et al.BJU international (Papier). 2011, Vol 108, Num 5, pp 679-686, issn 1464-4096, 8 p.Article

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJOHNSON, David H; FEHRENBACHER, Louis; HOLMGREN, Eric et al.Journal of clinical oncology. 2004, Vol 22, Num 11, pp 2184-2191, issn 0732-183X, 8 p.Article

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabINCE, William L; JUBB, Adrian M; KOEPPEN, Hartmut et al.Journal of the National Cancer Institute. 2005, Vol 97, Num 13, pp 981-989, issn 0027-8874, 9 p.Article

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancerSMITH, Matthew R; KABBINAVAR, Fairooz; LINNARTZ, Ronald et al.Journal of clinical oncology. 2005, Vol 23, Num 13, pp 2918-2925, issn 0732-183X, 8 p.Article